Epigenetic Mechanisms in Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) arises through a complex interplay of genetic mutations and epigenetic dysregulation, the latter encompassing heritable changes in gene expression that do not alter the underlying DNA sequence. Central among these are DNA methylation and histone post-translational modifications, which jointly govern chromatin architecture and transcriptional programmes. Aberrant hypermethylation of promoter CpG islands can silence tumour-suppressor genes, while global hypomethylation may activate oncogenic pathways and promote genomic instability. Histone acetylation, methylation and phosphorylation further modulate nucleosome dynamics, influencing access to key regulatory loci. Non-coding RNAs, including microRNAs and long non-coding RNAs, fine-tune these epigenetic landscapes by targeting both chromatin-remodelling complexes and messenger RNAs. These epigenetic alterations underpin critical hallmarks of HCC development—cell proliferation, evasion of apoptosis, angiogenesis, metastasis and immune escape—and offer avenues for biomarker discovery and targeted intervention at the level of epigenetic enzymes and reader domains.

Research from Nature Portfolio

A recent high-throughput study has identified a DNA methylation signature comprising a minimal set of CpG sites that reliably distinguishes HCC from healthy liver tissue and non-hepatocellular malignancies in liquid biopsy samples. By leveraging next-generation sequencing and multiplexed assay design, researchers validated a classifier based on only four CpG markers across diverse patient cohorts, achieving sensitivity and specificity in excess of 80 % and 95 %, respectively. This work demonstrates the potential for non-invasive early detection of HCC and underlines the clinical utility of epigenetic biomarkers in plasma.

Epigenetic Mechanisms in Hepatocellular Carcinoma publication trend

The graph below shows the total number of articles in epigenetic mechanisms in hepatocellular carcinoma across all publications each year (not limited to Nature Index journals).

Technical terms

DNA methylation: Addition of methyl groups to cytosine bases in CpG dinucleotides, modulating gene expression by altering chromatin structure.

Histone modification: Post-translational alterations to histone proteins (e.g. acetylation, methylation) that regulate nucleosome stability and accessibility of DNA.

Non-coding RNA (ncRNA): RNA molecules (such as microRNAs and lncRNAs) that do not encode proteins but regulate gene expression and epigenetic machinery.

CpG site: Genomic duo of cytosine and guanine nucleotides connected by a phosphate bond; hotspots for DNA methylation.

DNA methyltransferase (DNMT1): Enzyme responsible for maintaining methylation patterns during DNA replication, often upregulated in cancer.

References

1. A high-throughput test enables specific detection of hepatocellular carcinoma. Nature Communications (2023).
2. DNA methylation-activated full-length EMX1 facilitates metastasis through EMX1-EGFR-ERK axis in hepatocellular carcinoma. Cell Death & Disease (2023).
3. The activation of mTOR signalling modulates DNA methylation by enhancing DNMT1 translation in hepatocellular carcinoma. Journal of Translational Medicine (2023).
4. Targeted silencing of SOCS1 by DNMT1 promotes stemness of human liver cancer stem-like cells. Cancer Cell International (2024).